Oliver Wyman Webinar w/ Ivan Griffin

Join Ivan Griffin, BenevolentAI’s COO and Co-Founder, for a webinar on using AI and machine learning to transform drug discovery.

Artificial intelligence and machine learning are rapidly reshaping the healthcare landscape. By tapping into these analytic tools, pharma can develop better targeted care solutions. With 9 out of 10 candidate therapies failing somewhere between phase I trials and regulatory approval, new drug development—which can cost nearly $2.6 billion according to some estimates—is ripe for disruption. AI and machine learning has the potential to help the industry develop more effective drugs quicker and at a lower cost.

Dr Ivan Griffin, COO & Co-Founder of BenevolentAI, will share his views on the industry and how it could develop.

Link to event -->

Ivan Griffin

COO & Co-Founder, BenevolentAI

Ivan is COO and a Co-Founder of BenevolentAI. He has 10 years’ experience as a venture capitalist encompassing all aspects of technology commercialization; identification of opportunities, company formation, business development, private and public equity financings and trade sales. He also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Ivan holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where he also completed a year’s post-doctoral research.

More Posts

You Might Also Like

Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022